^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Melanoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    EVX-01 (Immunostimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    GlobeNewswire
    Title:

    Evaxion receives FDA fast-track designation for personalized cancer immunotherapy

    Published date:
    01/19/2023
    Excerpt:
    Evaxion Biotech...announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for the Company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA®....Evaxion received FDA approval to proceed with its Phase 2b clinical trial, where EVX-01 is given in combination with KEYTRUDA® to patients with metastatic melanoma.